A panel of experts today voted against Capricor’s cell therapy for Duchenne muscular dystrophy, capping off an advisory committee meeting marked by statistical confusion.
FDA adcomm shoots down Capricor's Duchenne cell therapy after meeting marked by statistical dispute
